|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: HIV - Change of Guard
Datamonitor, Dec 2006, Pages: 157
The HIV market generated $7.4 billion of sales in 2005 and experienced a CAGR of 13.3% from 2001-2005, making it one of the fastest growing infectious diseases sub sectors. Despite the antiretroviral markets relative immaturity, many older flagship products such as Combivir are expected to lose patent protection before 2015.
Scope of this title:
- In-depth analysis of the current HIV market across the major Western markets (US, France, Germany, Italy, Spain, UK)
- Thorough assessment of underlying commercial and clinical influencing factors shaping the antiretroviral market
- Detailed sales forecasts for the three major antiretroviral classes, molecules and brands in each of the six major markets
- Case study analysis of the competitive environment and critical success factors in the Protease Inhibitor class
Highlights of this title:
- By 2015 the global antibacterial market is forecast to be valued at more than $10 billion with a modest CAGR of 4.1%. The main contributor to growth will be the new drug classes such as integrase- and entry inhibitors.
- Since the advent of HAART, HIV has turned into a chronic disease with an average life expectancy similar to that of Type 2 diabetes, emphasizing the importance of side effect profiles associated with long-term use.
- The launch of several new products from new classes such as integrase inhibitors, CCR5 inhibitors from 2007, and recently launched PIs, will cause the salvage market to decline. Despite proven synergy between Fuzeon and the new drugs, use of the former is predicted to decline.
Reasons to order your copy:
- Understand the constantly evolving market dynamics of antiretroviral (ARV) drugs
- Explore the impact of pending patent expiries and generic incursion on the ARV market, including product-specific case studies
- Obtain full global, country, class and product-specific forecasts of currently marketed and pipeline ARVs from 2005 to 2015.
Customers who bought this item also bought
Stakeholder Opinions: HIV - Reaching the Untapped Patient Population
HIV Resistance: Impact and Evolution
Strategic Analysis of Global HIV Diagnostics and Monitoring Markets
Stakeholder Opinions: HIV/ HBV Co-infection - More Potency, More Policy
Stakeholder Opinions: HIV/HCV Co-infection - Whose Niche?
Commercial Insight: Antibacterials - Growth in Resistance Rates Drives Niche Indications
Pipeline Insight: HIV - Enter the New Generation Inhibitors
HIV Update 2002 (10) - October
|
|
|
|
